Buprenorphine Patent Expiration
Buprenorphine is Used for chronic pain management when other treatment options are inadequate, requiring long-term around-the-clock opioid therapy. It was first introduced by Knoa Pharma Llc
Buprenorphine Patents
Given below is the list of patents protecting Buprenorphine, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Sublocade | US10646484 | Methods to treat opioid use disorder | Jun 22, 2038 | Indivior |
| Sublocade | US11000520 | Buprenorphine dosing regimens | Nov 06, 2035 | Indivior |
| Sublocade | US11839611 | Buprenorphine dosing regimens | Nov 06, 2035 | Indivior |
| Sublocade | US12622904 | Buprenorphine Dosing Regimens | Nov 06, 2035 | Indivior |
| Brixadi | US10912772 | Opioid formulations | Jul 26, 2032 | Braeburn |
| Brixadi | US11110084 | Opioid formulations | Jul 26, 2032 | Braeburn |
| Brixadi | US11135215 | Opioid formulations | Jul 26, 2032 | Braeburn |
| Brixadi | US12161640 | Opioid formulations | Jul 26, 2032 | Braeburn |
| Brixadi | US12318379 | Opioid Formulations | Jul 26, 2032 | Braeburn |
| Brixadi | US9937164 | Opioid formulations | Jul 26, 2032 | Braeburn |
| Sublocade | US8921387 | Injectable flowable composition comprising buprenorphine | Jan 06, 2032 | Indivior |
| Sublocade | US8975270 | Injectable flowable composition comprising buprenorphine | Sep 05, 2031 | Indivior |
| Sublocade | US10558394 | Injectable flowable composition comprising buprenorphine | Jun 25, 2031 | Indivior |
| Sublocade | US10198218 | Injectable flowable composition comprising buprenorphine | Jun 06, 2031 | Indivior |
| Sublocade | US10592168 | Injectable flowable composition comprising buprenorphine | Jun 06, 2031 | Indivior |
| Sublocade | US9272044 | Injectable flowable composition buprenorphine | Jun 06, 2031 | Indivior |
| Sublocade | US9498432 | Injectable flowable composition comprising buprenorphine | Jun 06, 2031 | Indivior |
| Sublocade | US9782402 | Injectable composition comprising buprenorphine | Jun 06, 2031 | Indivior |
| Sublocade | US9827241 | Injectable flowable composition comprising buprenorphine | Jun 06, 2031 | Indivior |
| Brixadi | US8236292 | Liquid depot formulations | Jan 10, 2027 | Braeburn |
| Brixadi | US8236755 | Opioid depot formulations |
Jul 31, 2026
(Expired) | Braeburn |
| Brixadi | US8545832 | Lipid depot formulations |
Jun 06, 2025
(Expired) | Braeburn |
| Butrans | US9642850 | Method of providing sustained analgesia with buprenorphine |
Sep 29, 2017
(Expired) | Knoa Pharma |
| Butrans | USRE41408 | Method of providing sustained analgesia with buprenorpine |
Sep 29, 2017
(Expired) | Knoa Pharma |
| Butrans | USRE41489 | Method of providing sustained analgesia with buprenorphine |
Sep 29, 2017
(Expired) | Knoa Pharma |
| Butrans | USRE41571 | Method of providing sustained analgesia with buprenorphine |
Sep 29, 2017
(Expired) | Knoa Pharma |
| Butrans | US6264980 | Transdermal resorption of active substances from supercooled masses of levulic acid |
Dec 18, 2015
(Expired) | Knoa Pharma |
| Butrans | US6344211 | Transdermal absorption of active substances from subcooled melts |
Dec 18, 2015
(Expired) | Knoa Pharma |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Buprenorphine's patents.
Latest Legal Activities on Buprenorphine's Patents
Given below is the list recent legal activities going on the following patents of Buprenorphine.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 19 May, 2025 | US9827241 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 01 Apr, 2025 | US9782402 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 18 Sep, 2024 | US11000520 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 16 May, 2024 | US9498432 |
| Patent Issue Date Used in PTA Calculation Critical
| 12 Dec, 2023 | US11839611 |
| Recordation of Patent eGrant | 12 Dec, 2023 | US11839611 |
| Mail Patent eGrant Notification | 12 Dec, 2023 | US11839611 |
| Email Notification Critical
| 12 Dec, 2023 | US11839611 |
| Patent eGrant Notification | 12 Dec, 2023 | US11839611 |
| Recordation of Patent Grant Mailed Critical
| 12 Dec, 2023 | US11839611 |
About Veterinary Buprenorphine
Buprenorphine is used in drugs marketed by 2 different companies: Elanco Us Inc, Zoetis Inc.
Other drugs containing Buprenorphine are: Zorbium , Simbadol .
Veterinary Buprenorphine Patents
Given below is the list of patents protecting Buprenorphine, along with the drug name that holds that patent and the company owning that drug.
Buprenorphine's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Buprenorphine:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
